In the past decade, genetic testing in prostate cancer has gained increasing popularity, both in research and clinical application. While sequencing studies continue to depict details of genomic variants, potential clinical indications for genetic testing in prostate cancer have expanded across the entire disease spectrum, from risk prediction in mutation carriers and patients with localized disease to therapy planning and selection in advanced disease stages.
Clinically, as therapy options for prostate cancer continue to advance and diversify, there is an increasing need for individualized, meticulous treatment selection and sequence planning, which may further prolong patient survival and maximize treatment benefits. The application of genomic knowledge and genetic testing to prostate cancer management provides important opportunities for optimizing patient outcomes and generates valuable clinical informatics for driving future advancements in the field.
A vast amount of work remains to be done. Association studies will continue to discover clinically significant, potentially actionable mutations in specific patient populations. Basic science studies are needed to elucidate the molecular mechanisms that underlie these mutations. Clinical trials and real-world studies will help to translate knowledge into practice.
The goal of this Research Topic is to facilitate the integration of research data and scientific knowledge in prostate cancer genomics, and ultimately to bring about feasible applications of novel diagnostic, therapeutic, and management options for prostate cancer patients across different disease stages and converge on basic principles and good clinical practice.
We welcome authors from all disciplines involved in this topic to submit articles of any eligible Frontiers in Oncology article type (preferably, but not limited to, Original Research, Clinical Trial, Systematic Review, and Perspective). It is our aim to attract a diversified collection of current research in the area, to reflect on the width and depth of genomic studies in prostate cancer.
This scope of this collection encompasses, but is not limited to, the following themes on prostate cancer genomics:
• Sequencing and understanding of the genomic landscape of prostate cancer, including different disease stages, phenotypes, and ethnic profiles.
• The prognostic and familial implications of germline mutations in prostate cancer.
• Genetic testing and risk-stratification in localized prostate cancer.
• Advancements in genetic testing technologies for prostate cancer, from tissue collection and histopathology to gene coverage.
• Genetic testing for predicting eligibility, response, tolerability, and resistance to systemic therapies in advanced-stage patients (e.g. chemotherapy, radiotherapy, targeted therapies, and immune checkpoint inhibitors).
• The underlying molecular basis of these pharmacological differences.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
In the past decade, genetic testing in prostate cancer has gained increasing popularity, both in research and clinical application. While sequencing studies continue to depict details of genomic variants, potential clinical indications for genetic testing in prostate cancer have expanded across the entire disease spectrum, from risk prediction in mutation carriers and patients with localized disease to therapy planning and selection in advanced disease stages.
Clinically, as therapy options for prostate cancer continue to advance and diversify, there is an increasing need for individualized, meticulous treatment selection and sequence planning, which may further prolong patient survival and maximize treatment benefits. The application of genomic knowledge and genetic testing to prostate cancer management provides important opportunities for optimizing patient outcomes and generates valuable clinical informatics for driving future advancements in the field.
A vast amount of work remains to be done. Association studies will continue to discover clinically significant, potentially actionable mutations in specific patient populations. Basic science studies are needed to elucidate the molecular mechanisms that underlie these mutations. Clinical trials and real-world studies will help to translate knowledge into practice.
The goal of this Research Topic is to facilitate the integration of research data and scientific knowledge in prostate cancer genomics, and ultimately to bring about feasible applications of novel diagnostic, therapeutic, and management options for prostate cancer patients across different disease stages and converge on basic principles and good clinical practice.
We welcome authors from all disciplines involved in this topic to submit articles of any eligible Frontiers in Oncology article type (preferably, but not limited to, Original Research, Clinical Trial, Systematic Review, and Perspective). It is our aim to attract a diversified collection of current research in the area, to reflect on the width and depth of genomic studies in prostate cancer.
This scope of this collection encompasses, but is not limited to, the following themes on prostate cancer genomics:
• Sequencing and understanding of the genomic landscape of prostate cancer, including different disease stages, phenotypes, and ethnic profiles.
• The prognostic and familial implications of germline mutations in prostate cancer.
• Genetic testing and risk-stratification in localized prostate cancer.
• Advancements in genetic testing technologies for prostate cancer, from tissue collection and histopathology to gene coverage.
• Genetic testing for predicting eligibility, response, tolerability, and resistance to systemic therapies in advanced-stage patients (e.g. chemotherapy, radiotherapy, targeted therapies, and immune checkpoint inhibitors).
• The underlying molecular basis of these pharmacological differences.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
